Smartleaf Asset Management’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.35K Sell
58
-14
-19% -$601 ﹤0.01% 2993
2026
Q2
$2.6K Hold
72
– – ﹤0.01% 2884
2026
Q1
$1.22K Hold
72
– – ﹤0.01% 3078
2025
Q4
$1.67K Hold
72
– – ﹤0.01% 3037
2025
Q3
$1.38K Buy
+72
New +$1.29K ﹤0.01% 2690

Other funds holding URGN

Smartleaf Asset Management's URGN Position: Q3 2026 in Review

Smartleaf Asset Management reduced its UroGen Pharma (URGN) stake by 19% in Q3 2026, selling an estimated $601 and leaving 58 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #2993.

Smartleaf Asset Management first reported a position in URGN in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.6K in Q2 2026. 219 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • Smartleaf Asset Management held 58 shares of UroGen Pharma worth $2.35K as of Q3 2026.
  • Smartleaf Asset Management sold 14 UroGen Pharma shares in Q3 2026, an estimated $601.
  • UroGen Pharma made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2993 holding.
  • Smartleaf Asset Management first reported a position in UroGen Pharma in Q3 2025 and has held it in 5 quarters since.
  • Smartleaf Asset Management's UroGen Pharma position peaked at $2.6K in Q2 2026.
  • 219 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.